CLINILABS SELECTED FOR A PHASE I/II STUDY OF HIV VACCINE
New York, NY (September 3, 2010) - Clinilabs,a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced today that they have been selected to conduct a Phase I/II clinical research study of an investigational vaccine for HIV.
Enrollment for this study is expected to begin later this month. Individuals in the New York City Metro area who are interested in participation may contact our dedicated recruitment staff at 212-994-4567 to prequalify. Healthy adult volunteers as well as HIV positive individuals who have a T-Cell count of 500 or more, may be eligible. Additional information may also be found by visiting www.clinilabs.com/volunteers.
Clinilabs is a contract research organization (CRO) that provides early-phase and specialty clinical drug development services to industry. We offer teams, processes, and technology solutions that are designed to serve single center and multicenter early-phase studies - services that can be scaled as needed to meet the requirements of any clinical development program. For more information, visit www.clinilabs.com .